Billets de Michelle Dawson

Billet publié sur Twitter/X le 03/10/2022 04:48

Retour aux billets Billet précédent Billet suivant
Twitter/X Essai clinique clinicaltrials.gov Extrait cité dans le billet Question posée par Dawson dans le billet Lien intégré au billet Termes sur l’autisme
Ouvrir le billet original

1 réponse intégrée de Michelle Dawson

03/10/2022 04:53

Note: that makes 3 very similar (except for the drug being tested) trial registrations so far--for anyone keeping track, here are the other 2
https://t.co/Ik9CODwtB4
&
https://t.co/tGjb98LqQt

Voir la réponse sur Twitter/X

Infos sur le lien intégré au billet

Essai clinique

Stanford University, National Institutes of Health (NIH) (2023). Trial of Suvorexant for Sleep in Children With Autism. ClinicalTrials.gov. Stanford University.

Plus d’infos

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Stanford University, National Institutes of Health (NIH) (2023). Trial of Suvorexant for Sleep in Children With Autism. ClinicalTrials.gov. Stanford University.

Date de publication
09/08/2023
Identifiant
NCT05546554
Auteurs
Stanford University, National Institutes of Health (NIH)
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Stanford University
Source de métadonnées
clinicaltrials.gov

Résumé

The purpose of this study is to examine the effect of suvorexant on sleep in children and adolescents with Autism Spectrum Disorder (ASD). Suvorexant is a selective, dual orexin receptor antagonist (DORA) used for the treatment of sleep onset difficulties and/or sleep maintenance. To accomplish this, the investigators will use a randomized double-blind placebo-controlled crossover 8-week study design to examine the effect of suvorexant on sleep physiology as assessed by polysomnography (PSG), actigraphy, circadian rhythm, and clinical measures.

Ouvrir la source